Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InnaVirVax, a developer of therapeutic and diagnostic solutions for immune dysregulations, has reported positive preclinical results of its therapeutic vaccine VAC-3S, which preserves the immune system of patients infected with HIV-1.
Subscribe to our email newsletter
VAC-3S is designed to fight the pathogenicity of the virus by blocking the decrease of the CD4 + T lymphocytes cell count.
The VAC-3S project was supported by the French National Research Agency, as part of a collaborative project with the UMRS 946 and the ‘Comissariat à l’Energie Atomique’.
The studies of toxicity and local tolerance of the vaccine candidate VAC-3S have just been completed under good laboratory practice (GLP) at the CIT (Evreux, France), the results showed the absence of toxicity of the vaccine.
The company intends to start Phase I / IIa clinical studies in that the main objective of the trial will focus on the safety and immunogenicity of VAC-3S in patients infected with HIV-1.
Some efficacy parameters such as CD4 count, viral load and cellular activation will be studied during as secondary objective.
InnaVirVax CEO Joel Crouzet said the protection and preservation of CD4+ T lymphocyte cells provide a response to HIV-infected patients treated or untreated with antiretroviral drugs at different stages of disease progression.